The resurgence of covalent drugs

Nature Reviews Drug Discovery

Volumn 10, Issue 4, 2011, Pages 307-317

  Singh, Juswinder ^a   Petter, Russell C ^a   Baillie, Thomas A ^b   Whitty, Adrian ^c  

^a Avila Therapeutics Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 3 NITROBENZAMIDE; ABIRATERONE; ACETYLSALICYLIC ACID; AFATINIB; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CARFILZOMIB; CENTRAL NERVOUS SYSTEM AGENTS; CLOPIDOGREL; COVALENT DRUG; DRUG; ESOMEPRAZOLE; GASTROINTESTINAL AGENT; GENERIC DRUG; LANSOPRAZOLE; NERATINIB; OMEPRAZOLE; PCI 32765; PENICILLIN DERIVATIVE; PF 299804; RASAGILINE; ROCEPREVIR; SELEGILINE; TELAPREVIR; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEPRESSION; DRUG APPROVAL; DRUG BINDING; DRUG DESIGN; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG USE; GASTROINTESTINAL REFLUX; HUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; VASCULAR DISEASE;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953314480     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3410     Document Type: Review

References (71)

1. Potashman, M. H. & Duggan, M. E. Covalent modifiers: an orthogonal approach to drug design. J. Med. Chem. 52, 1231-1246 (2009).
2. Robertson, J. G. Mechanistic basis of enzyme- targeted drugs. Biochemistry 44, 5561-5571 (2005). (Pubitemid 40528448)
3. Bartholow, M. Top 200 Prescription Drugs of 2009. Pharmacy Times [online], http://www.pharmacytimes.com/issue/pharmacy/2010/May2010/ RxFocusTopDrugs-0510 (2010).
4. Jeffreys, D. Aspirin: The Remarkable Story of a Wonder Drug (Bloomsbury, New York, 2004).
5. Dixon, J. M. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment. Expert. Rev. Anticancer Ther. 2, 267-275 (2002). (Pubitemid 34679482)
6. Thomas, D. M. & Zalcberg, J. R. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin. Exp. Pharmacol. Physiol. 25, 887-895 (1998). (Pubitemid 28500827)
7. Xu, H., Faber, C., Uchiki, T., Racca, J. & Dealwis, C. Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. Proc. Natl Acad. Sci. USA 103, 4028-4033 (2006).
8. Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001). (Pubitemid 32758501)
9. Esplugues, J. V. & Marti-Cabrera, M. Safety and interactions of proton pump inhibitors: lessons learned in millions of patients. Gastroenterol. Hepatol. 33 (Suppl. 1), 15-21 (2010).
10. Oldfield, V., Keating, G. M. & Perry, C. M. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs 67, 1725-1747 (2007). (Pubitemid 47263179)
11. Savi, P. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891-896 (2000).
12. Warner, T. D. & Mitchell, J. A. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc. Natl Acad. Sci. USA 99, 13371-13373 (2002). (Pubitemid 35215385)
13. Waxman, D. J. & Strominger, J. L. Penicillin-binding proteins and the mechanism of action of β-lactam antibiotics. Annu. Rev. Biochem. 52, 825-869 (1983). (Pubitemid 13030694)
14. Olbe, L., Carlsson, E. & Lindberg, P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nature Rev. Drug Discov. 2, 132-139 (2003). (Pubitemid 37361645)
15. Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. Nature 432, 855-861 (2004). (Pubitemid 40037141)
16. Erve, J. C. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert. Opin. Drug Metab. Toxicol. 2, 923-946 (2006). (Pubitemid 44911540)
17. Uetrecht, J. Immune-mediated adverse drug reactions. Chem. Res. Toxicol. 22, 24-34 (2009).
18. Baillie, T. A. Future of toxicology - metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19, 889-893 (2006). (Pubitemid 44092354)
19. Liebler, D. C. Protein damage by reactive electrophiles: targets and consequences. Chem. Res. Toxicol. 21, 117-128 (2008). (Pubitemid 351219713)
20. Kumar, S., Kassahun, K., Tschirret-Guth, R. A., Mitra, K. & Baillie, T. A. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. Curr. Opin. Drug Discov. Devel. 11, 43-52 (2008).
21. Lammert, C. et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47, 2003-2009 (2008). (Pubitemid 351945567)
22. Zhang, D. et al. Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans. Drug Metab. Dispos. 33, 83-93 (2005). (Pubitemid 40023518)
23. Tummino, P. J. & Copeland, R. A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47, 5481-5492 (2008). (Pubitemid 351711169)
24. Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nature Rev. Drug Discov. 5, 730-739 (2006). (Pubitemid 44323700)
25. Copeland, R. A. Evaluation of enzyme inhibitors in drug discovery: A guide for medicinal chemists and pharmacologists. 1-265 (Wiley, Hoboken, New Jersey, 2005).
26. Lu, H. & Tonge, P. J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467-474 (2010).
27. Rajashekhar, B., Fitzpatrick, P. F., Colombo, G. & Villafranca, J. J. Synthesis of several 2-substituted 3-(p-hydroxyphenyl)-1-propenes and their characterization as mechanism-based inhibitors of dopamine β-hydroxylase. J. Biol. Chem. 259, 6925-6930 (1984). (Pubitemid 14077823)
28. Wu, J. C. & Fritz, L. C. Irreversible caspase inhibitors: tools for studying apoptosis. Methods 17, 320-328 (1999). (Pubitemid 29440607)
29. Ahn, K. et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16, 411-420 (2009).
30. Kuntz, I. D., Chen, K., Sharp, K. A. & Kollman, P. A. The maximal affinity of ligands. Proc. Natl Acad. Sci. USA 96, 9997-10002 (1999). (Pubitemid 29422500)
31. Hopkins, A. L., Groom, C. R. & Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9, 430-431 (2004). (Pubitemid 38510559)
32. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem. 49, 6972-6976 (2006). (Pubitemid 44885985)
33. Smith, A. J., Zhang, X., Leach, A. G. & Houk, K. N. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J. Med. Chem. 52, 225-233 (2009).
34. Wissner, A. et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 46, 49-63 (2003). (Pubitemid 36043786)
35. Jencks, W. P. Binding energy, specificity, and enzymic catalysis: the circe effect. Adv. Enzymol. Relat. Areas Mol. Biol. 43, 219-410 (1975).
36. Menger, F. M. On the source of intramolecular and enzymatic reactivity. Acc. Chem. Res. 18, 128-134 (1985).
37. Puente, X. S., Sanchez, L. M., Overall, C. M. & Lopez-Otin, C. Human and mouse proteases: a comparative genomic approach. Nature Rev. Genet. 4, 544-558 (2003). (Pubitemid 36781345)
38. Turk, B. Targeting proteases: successes, failures and future prospects. Nature Rev. Drug Discov. 5, 785-799 (2006). (Pubitemid 44323703)
39. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075-13080 (2010).
40. Hagel, M. Selective irreversible inhibition of a protease by targeting a non-catalytic cysteine. Nature Chem. Biol. 7, 22-24 (2010).
41. Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H. & Schramm, V. L. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J. Biol. Chem. 278, 31465-31468 (2003). (Pubitemid 37048321)
42. Sachs, G., Shin, J. M. & Howden, C. W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment. Pharmacol. Ther. 23 (Suppl. 2), 2-8 (2006). (Pubitemid 44383831)
43. Kwak, E. L. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102, 7665-7670 (2005). (Pubitemid 40741028)
44. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
45. Carter, T. A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011-11016 (2005). (Pubitemid 41105984)
46. Yun, C. H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070-2075 (2008).
47. Singh, J. et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40, 1130-1135 (1997). (Pubitemid 27149266)
48. Fry, D. W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther. 82, 207-218 (1999). (Pubitemid 29255916)
49. Wissner, A. & Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer. Arch. Pharm. (Weinheim) 341, 465-477 (2008).
50. Cohen, M. S., Zhang, C., Shokat, K. M. & Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321 (2005). (Pubitemid 40746129)
51. Zhou, W. et al. A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol. 17, 285-295 (2010).
52. Schirmer, A., Kennedy, J., Murli, S., Reid, R. & Santi, D. V. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc. Natl Acad. Sci. USA 103, 4234-4239 (2006).
53. Choi, S., Connelly, S., Reixach, N., Wilson, I. A. & Kelly, J. W. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nature Chem. Biol. 6, 133-139 (2010).
54. Fry, D. W. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des. 15, 3-16 (2000). (Pubitemid 30364895)
55. Fry, D. W. et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl Acad. Sci. USA 95, 12022-12027 (1998). (Pubitemid 28460532)
56. Gan, J., Harper, T. W., Hsueh, M. M., Qu, Q. & Humphreys, W. G. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18, 896-903 (2005). (Pubitemid 40705457)
57. Torrance, C. J. et al. Combinatorial chemoprevention of intestinal neoplasia. Nature Med. 6, 1024-1028 (2000).
58. Chandrasekaran, A. et al. Reversible covalent binding of neratinib to human serum albumin in vitro. Drug Metab. Lett. 4, 220-227 (2010).
59. Wang, J. et al. Characterization of HKI-272 covalent binding to human serum albumin. Drug Metab. Dispos. 38, 1083-1093 (2010).
60. Johnson, D. S., Weerapana, E. & Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2, 949-964 (2010).
61. Yap, T. A. et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28, 3965-3972 (2010).
62. Gonzales, A. J. et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 7, 1880-1889 (2008).
63. Burstein, H. J. et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28, 1301-1307 (2010).
64. Singh, J., Petter, R. C. & Kluge, A. F. Targeted covalent drugs of the kinase family. Curr. Opin. Chem. Biol. 14, 475-480 (2010).
65. Vogiatzi, P. & Claudio, P. P. Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer. Expert. Rev. Anticancer Ther. 10, 1027-1030 (2010).
66. O'Connor, O. A. et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15, 7085-7091 (2009).
67. Ryan, C. J. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28, 1481-1488 (2010).
68. O'Shaughnessy, J. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214 (2011).
69. Lin, C., Kwong, A. D. & Perni, R. B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS34A serine protease. Infect. Disord. Drug Targets 6, 3-16 (2006). (Pubitemid 43796632)
70. Kwo, P. Y. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705-716 (2010).
71. Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K. & Isakson, P. C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 339, 607-614 (1999). (Pubitemid 29243524)